These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 31069016)
1. Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach. Xiao Z; Sperl B; Gärtner S; Nedelko T; Stacher-Priehse E; Ullrich A; Knyazev PG Oncotarget; 2019 Apr; 10(26):2546-2560. PubMed ID: 31069016 [TBL] [Abstract][Full Text] [Related]
2. Correction: Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach. Xiao Z; Sperl B; Gärtner S; Nedelko T; Stacher-Priehse E; Ullrich A; Knyazev PG Oncotarget; 2021 Aug; 12(17):1734-1735. PubMed ID: 34434503 [TBL] [Abstract][Full Text] [Related]
3. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724 [TBL] [Abstract][Full Text] [Related]
4. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Segura-Carretero A; Joven J; Martin-Castillo B; Barrajón-Catalán E; Micol V; Bosch-Barrera J; Menendez JA Cell Cycle; 2013 Nov; 12(21):3390-404. PubMed ID: 24047698 [TBL] [Abstract][Full Text] [Related]
5. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations. Endo H; Okami J; Okuyama H; Nishizawa Y; Imamura F; Inoue M Oncogene; 2017 May; 36(20):2824-2834. PubMed ID: 27893711 [TBL] [Abstract][Full Text] [Related]
6. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115 [TBL] [Abstract][Full Text] [Related]
7. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling. Wang W; Xia X; Chen K; Chen M; Meng Y; Lv D; Yang H Front Oncol; 2021; 11():665045. PubMed ID: 34168988 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. Togashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K J Thorac Oncol; 2015 Jan; 10(1):93-101. PubMed ID: 25384171 [TBL] [Abstract][Full Text] [Related]
9. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402 [TBL] [Abstract][Full Text] [Related]
10. Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway. Li L; Wang T; Hu M; Zhang Y; Chen H; Xu L Front Oncol; 2020; 10():1605. PubMed ID: 33014814 [No Abstract] [Full Text] [Related]
11. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010 [TBL] [Abstract][Full Text] [Related]
12. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Wnt/β-catenin pathway reverses multi-drug resistance and EMT in Oct4 Liu L; Zhu H; Liao Y; Wu W; Liu L; Liu L; Wu Y; Sun F; Lin HW Biomed Pharmacother; 2020 Jul; 127():110225. PubMed ID: 32428834 [TBL] [Abstract][Full Text] [Related]
14. Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. Xiao Z; Sperl B; Ullrich A; Knyazev P Oncotarget; 2014 Dec; 5(24):12877-90. PubMed ID: 25375092 [TBL] [Abstract][Full Text] [Related]
15. Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025 [TBL] [Abstract][Full Text] [Related]
16. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308 [TBL] [Abstract][Full Text] [Related]
17. Alveolar progenitor and stem cells in lung development, renewal and cancer. Desai TJ; Brownfield DG; Krasnow MA Nature; 2014 Mar; 507(7491):190-4. PubMed ID: 24499815 [TBL] [Abstract][Full Text] [Related]